Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.85 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911637 | 0.97 | CSF1R (0.94) | CSF1RKCNH2SCN5A | |
| SCHEMBL2908149 | 0.94 | CSF1R (0.94) | CSF1RKCNH2SCN5A | |
| SCHEMBL2904081 | 0.93 | CSF1R (0.87) | CSF1RKCNH2SCN5A | |
| SCHEMBL2913869 | 0.92 | CSF1R (0.86) | CSF1RKCNH2SCN5A | |
| SCHEMBL1276777 | 0.92 | CSF1R (1.00) | CSF1RKCNH2SCN5A | |
| SCHEMBL29411758 | 0.92 | CSF1R (1.00) | CSF1RKCNH2SCN5A | |
| SCHEMBL2909797 | 0.92 | CSF1R (0.85) | CSF1RKCNH2SCN5A | |
| SCHEMBL2908798 | 0.92 | CSF1R (0.85) | CSF1RKCNH2SCN5A | |
| SCHEMBL1276809 | 0.91 | CSF1R (0.84) | CSF1RKCNH2SCN5A | |
| SCHEMBL2913703 | 0.91 | CSF1R (0.83) | CSF1RKCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210071258-A1 | GENE EXPRESSION AND ASSESSMENT OF RISK OF DEVELOPING TOXICITY FOLLOWING CELL THERAPY | JUNO THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| EP-2010496-B1 | 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-25 | — | — | EP | disclosed |